PDT Partners LLC acquired a new stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 75,144 shares of the biotechnology company's stock, valued at approximately $1,744,000. PDT Partners LLC owned 0.28% of Arcturus Therapeutics at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Russell Investments Group Ltd. purchased a new stake in shares of Arcturus Therapeutics in the 1st quarter valued at $40,000. nVerses Capital LLC purchased a new stake in Arcturus Therapeutics during the 3rd quarter worth about $42,000. Quest Partners LLC increased its holdings in Arcturus Therapeutics by 3,283.5% during the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company's stock worth $90,000 after purchasing an additional 3,579 shares during the period. CANADA LIFE ASSURANCE Co increased its holdings in Arcturus Therapeutics by 10.5% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company's stock worth $152,000 after purchasing an additional 428 shares during the period. Finally, Public Employees Retirement System of Ohio increased its holdings in Arcturus Therapeutics by 63.8% during the 1st quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company's stock worth $156,000 after purchasing an additional 1,800 shares during the period. Hedge funds and other institutional investors own 94.54% of the company's stock.
Insider Buying and Selling at Arcturus Therapeutics
In other news, COO Pad Chivukula sold 12,000 shares of Arcturus Therapeutics stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total transaction of $249,120.00. Following the sale, the chief operating officer now directly owns 435,334 shares of the company's stock, valued at approximately $9,037,533.84. The trade was a 2.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 15.30% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on ARCT. Leerink Partners began coverage on Arcturus Therapeutics in a research report on Monday, August 12th. They set an "outperform" rating and a $70.00 price objective for the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. HC Wainwright reaffirmed a "buy" rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a research report on Friday, November 8th. Finally, Leerink Partnrs raised Arcturus Therapeutics to a "strong-buy" rating in a research report on Monday, August 12th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $71.40.
Read Our Latest Stock Analysis on Arcturus Therapeutics
Arcturus Therapeutics Stock Performance
Arcturus Therapeutics stock traded up $0.83 during mid-day trading on Friday, reaching $18.34. 201,909 shares of the company were exchanged, compared to its average volume of 483,471. Arcturus Therapeutics Holdings Inc. has a twelve month low of $14.93 and a twelve month high of $45.00. The firm has a market cap of $496.83 million, a PE ratio of -8.26 and a beta of 2.64. The firm's 50-day simple moving average is $19.91 and its two-hundred day simple moving average is $23.19.
Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.70) by $0.44. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The company had revenue of $41.67 million for the quarter, compared to analyst estimates of $49.16 million. During the same period last year, the company posted ($0.61) earnings per share. As a group, equities research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.31 EPS for the current year.
Arcturus Therapeutics Profile
(
Free Report)
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
See Also
Before you consider Arcturus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcturus Therapeutics wasn't on the list.
While Arcturus Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
